This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Pfizer (PFE) Seems Well-Poised for Long-Term Growth: Here's How
by Zacks Equity Research
Though Pfizer's (PFE) revenues from COVID products are declining sharply, it is set to launch some key non-COVID products in 2023, which can drive long-term sales and profit growth.
Top Analyst Reports for Oracle, Chevron & Linde
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Oracle Corporation (ORCL), Chevron Corporation (CVX) and Linde plc (LIN).
Pharma ETFs in Focus Post Q2 Earnings
by Sweta Killa
Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.
Mirati (MRTX) Q2 Earnings Beat, Stock Up on Solid Krazati Sales
by Zacks Equity Research
Mirati (MRTX) reports better-than-expected second-quarter earnings while revenues miss by a slight margin. Its CEO steps down. The stock climbs 9%.
Prothena (PRTA) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Prothena (PRTA) reports a wider-than-expected loss in the second quarter. The company makes considerable pipeline progress and updates 2023 bottom-line guidance.
Editas' (EDIT) Q2 Earnings Beat, Sales Miss, Pipeline in Focus
by Zacks Equity Research
Editas (EDIT) reports mixed second-quarter 2023 results. EDIT-301 studies remain on track to provide updates by the end of the year. The stock of the company rises about 6% on Wednesday.
Here's Why Investors Should Buy These 2 Medical Stocks After Earnings
by Shaun Pruitt
Following their favorable Q2 reports now looks like a good time to buy Encompass Health (EHC) and Vertex Pharmaceuticals (VRTX) stock.
Exelixis (EXEL) Q2 Earnings Top, Cabometyx Drives Growth
by Zacks Equity Research
Exelixis (EXEL) beats second-quarter 2023 earnings and sales estimates as Cabometyx drives growth in approved indications.
Pfizer's (PFE) Q2 Earnings Beat, Sales Miss, Stock Declines
by Zacks Equity Research
Pfizer (PFE) beats estimates for second-quarter earnings but misses the same for sales. It trims the upper end of its revenue guidance range for 2023. Stock falls.
How Will Pfizer's (PFE) Key Drugs Perform in Q2 Earnings?
by Zacks Equity Research
Higher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like Vyndaqel/Vyndamax are likely to have contributed to Pfizer's (PFE) sales growth in Q2.
Bristol-Myers (BMY) Q2 Earnings, Sales Miss, '23 View Lowered
by Zacks Equity Research
Bristol-Myers' (BMY) second-quarter 2023 earnings and sales miss estimates due to generic erosion for the oncology drug Revlimid. The company also cuts its forecast for 2023.
Compared to Estimates, Bristol Myers (BMY) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Bristol Myers Squibb (BMY) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Bristol Myers (BMY) delivered earnings and revenue surprises of -12.06% and 4.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Bristol-Myers (BMY) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q2 results.
Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Bristol Myers Squibb (BMY) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed the most recent trading day at $62.06, moving +0.1% from the previous trading session.
3 Top Dividend Stocks to Maximize Your Retirement Income
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Novartis (NVS) to Report Q2 Earnings: Is a Beat in Store?
by Zacks Equity Research
When Novartis (NVS) reports second-quarter 2023 results, investor focus is likely to be on updates related to Sandoz's spin-off besides the top- and bottom-line numbers.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Bristol Myers Squibb (BMY) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $62.28 in the latest trading session, marking no change from the prior day.
Biotech Stock Roundup: BIIB, Eisai's Drug Update, NVAX Gains on Deal Amendment
by Zacks Equity Research
Regulatory and key pipeline updates from Biogen (BIIB) and Novavax (NVAX) are in focus in the biotech sector.
Bristol Myers (BMY) Reports Positive Data From Urothelial Cancer Study
by Zacks Equity Research
Bristol Myers (BMY) meets its dual primary endpoint in the late-stage expansion study of Opdivo for the treatment of unresectable or metastatic urothelial carcinoma.